Why Your Flu Shot Works Less Well at 70: The New Science of Fixing Vaccines for Older Immune Systems
Aging immune systems mount weaker responses to vaccines. A new Nature Aging review maps the engineering — higher doses, smarter adjuvants, mRNA — designed to close the gap.
Roll up a sleeve at 35 and your immune system tends to read the vaccine like a sharp memo: short, urgent, acted on. Roll up the same sleeve at 75 and the memo still arrives — but it lands on a desk piled with older mail, in an office where the staff has thinned out and the lights flicker. The shot is the same. The reader is not. That mismatch, increasingly called immunosenescence, is why the people who most need protection from influenza, RSV, and COVID-19 often get the least from the standard versions of the vaccines designed to provide it. A 2025 review in Nature Aging argues the fix is no longer hypothetical: it's a toolkit of higher-dose antigens, next-generation adjuvants, mRNA platforms, and — more speculatively — drugs that target aging itself.
- The problem is the host, not the pathogen. Aging immune cells respond less vigorously to the same vaccine antigen, a phenomenon called immunosenescence.
- More antigen helps, but isn't the whole answer. High-dose formulations are one of several strategies reviewed for boosting older-adult responses.
- Adjuvants and mRNA platforms are being engineered specifically for older immune systems, alongside efforts toward universal vaccines.
- Geroscience is the wild card. Early clinical signals suggest interventions like mTOR inhibition may improve vaccine responses — promising, but not yet standard care.
- Evidence rating: Moderate. The mechanisms are well-described and several strategies are clinically deployed; head-to-head long-term outcomes data is still maturing.
What actually goes wrong with an older immune response
The shorthand "immunosenescence" covers a lot of ground. It includes thymic involution (the organ that schools new T cells shrinks with age), a narrower repertoire of naive lymphocytes available to recognize novel threats, and a chronic low-grade inflammatory tone — sometimes called "inflammaging" — that paradoxically blunts the sharp, targeted response a vaccine is trying to provoke. The Nature Aging review frames these as overlapping problems: an older immune system isn't simply weaker, it's miscalibrated, with the baseline noise turned up and the signal-detection turned down. That is the substrate every vaccine in a 70-year-old arm has to work against, and it's why the same dose that protects a 30-year-old can underperform in a 70-year-old by a meaningful margin.
The clinical consequence is familiar to anyone who has watched a flu season tear through a long-term care facility despite high vaccination rates. The vaccine wasn't a fraud. The immune system reading it had aged.
Higher-antigen formulations are one of several strategies aimed at older immune systems.
Strategy one: more antigen
The most intuitive fix is also the bluntest: give the older immune system more of what it's supposed to recognize. High-dose influenza vaccines — already in use in many countries for adults 65 and over — embody this approach. The Nature Aging review treats increased antigen quantity as one pillar of a multi-pillar strategy, useful but not sufficient on its own. More antigen can partially compensate for a less responsive system, but it does not reverse the underlying cellular aging that limits how robust and durable the response becomes in older adults.
An older immune system isn't simply weaker. It's miscalibrated — baseline noise turned up, signal detection turned down.
Strategy two: smarter adjuvants
Adjuvants are the supporting cast — molecules added to a vaccine to recruit and energize the immune cells that will then respond to the antigen. The newer generation reviewed by the authors aims not just to amplify the response generally, but to engage pathways that age-related changes have left underused. The thinking is mechanistic: if the problem is that older immune cells are slower to mobilize and quicker to default to inflammation rather than precise targeting, an adjuvant chosen to coax precise targeting may matter more than one that simply turns the volume up across the board.
Strategy three: mRNA, and the universal-vaccine ambition
mRNA platforms — vaulted into household familiarity by the COVID-19 pandemic — are being investigated not only as a faster way to make vaccines but as a substrate that may engage older immune systems differently than traditional protein-based shots. The review groups mRNA with another long-running ambition: universal vaccines, designed to elicit immunity against the conserved parts of viruses (the regions that don't change much from strain to strain), potentially freeing older adults from the annual guessing game of matching that year's circulating influenza to that year's formulation. Both are characterized in the review as promising rather than proven for the older-adult use case specifically; the underlying biology is plausible and early data is encouraging, but the long-term, head-to-head clinical record in older populations is still being built out.
Strategy four: treat the aging, not just the vaccine
The most speculative — and most interesting — section of the review concerns geroscience: the idea that interventions targeting aging biology itself could make whatever vaccine you give work better. The authors discuss emerging clinical evidence around mTOR inhibition and caloric restriction as candidate approaches, on the logic that they may attenuate chronic inflammation and the metabolic shifts that accompany immune aging in older adults. This is genuinely early science. It is not a regimen to adopt; it is a research direction to watch. The signal in the review is that the field is increasingly willing to ask whether the right intervention point is the vaccine, the immune system, or the aging process feeding both.
How strong is the evidence, really?
Moderate, and worth being precise about why. The biology of immunosenescence is well-described and reproducible. Several of the engineering strategies — higher-dose formulations, certain adjuvanted vaccines — are already in clinical use in older adults, supported by trials showing improved immunogenicity and, in some cases, improved clinical outcomes versus standard formulations. mRNA and universal-vaccine approaches are advancing but the older-adult-specific long-term efficacy data is still being generated. The geroscience strategies are the most preliminary: mechanistically compelling, with early clinical signals, but a long way from standard practice. The Nature Aging review's contribution is to set these in one frame — not to declare the problem solved, but to show that the toolkit for solving it is no longer empty .
The honest summary: the next decade of vaccine development for older adults will likely look less like one breakthrough and more like a layered set of fixes — more antigen here, a better adjuvant there, a new platform somewhere else, and, eventually perhaps, a pill that makes the immune system a little less old before the needle goes in.